The short answer
FLOW, registered as NCT03819153, was a completed Phase 3 trial of semaglutide against placebo in 3,533 participants with type 2 diabetes and chronic kidney disease. Perkovic and colleagues published results in the New England Journal of Medicine in July 2024.
Key facts
- Trial
- FLOW, NCT03819153
- Phase
- 3
- Enrolment
- 3,533
- Status
- Completed
- Population
- Type 2 diabetes with chronic kidney disease
- Published
- NEJM 2024 (PMID 38785209)
- Endpoint type
- Clinical events, not a surrogate
Why this is stronger evidence than a weight trial
The endpoint is events people care about, kidney failure, substantial loss of kidney function, death from kidney or cardiovascular causes. That is not a surrogate. A trial that counts hard clinical events over years is a more demanding and more informative exercise than one measuring percentage change in body weight over 68 weeks.
Why kidney disease was a plausible target
Diabetic kidney disease progresses through glomerular injury driven by hyperglycaemia, raised intraglomerular pressure and inflammation. A drug improving glycaemic control and reducing weight addresses several of those upstream, and incretin effects on inflammation and haemodynamics have been proposed as additional contributors.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The question the trial could not answer alone
Whether benefit came from glycaemic control, weight reduction, or a direct renal effect. Those travel together in the same participants, so a single trial cannot separate them. Mann and colleagues addressed part of this in Nature Medicine in 2024 by examining effects with and without concomitant SGLT2 inhibitor use. A class with established renal benefit through a different mechanism.
Why the SGLT2 comparison matters
If semaglutide's benefit were simply duplicating what SGLT2 inhibitors already do, the effect would shrink substantially in participants already taking one. Examining that subgroup is how a trial team interrogates its own mechanism rather than asserting it, and it is the kind of analysis worth looking for in any outcome trial.
How this reframes the drug class
A compound with a cardiovascular outcome trial, a kidney outcome trial and a liver histology trial is no longer straightforwardly a weight-loss drug. It is a metabolic agent with several indications, which is why the regulatory and prescribing picture has become considerably more complicated than the public conversation suggests.
What none of this concerns
Research material. FLOW studied a licensed medicine in a defined patient population under clinical supervision. Nothing supplied here is semaglutide or an alternative to any prescribed treatment for kidney disease.
Frequently asked questions
What did FLOW measure?
Hard clinical events, kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes. Not a surrogate endpoint.
How large was it?
3,533 participants with type 2 diabetes and chronic kidney disease. The trial is completed.
Was the benefit just from weight loss?
Not separable within one trial. The Nature Medicine analysis of participants with and without SGLT2 inhibitor use addresses part of the question.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedPerkovic V et al., Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. NEJM 2024 (PMID 38785209)pubmed.ncbi.nlm.nih.gov
- PubMedMann JFE et al., Effects of semaglutide with and without concomitant SGLT2 inhibitor use in FLOW. Nat Med 2024 (PMID 38914124)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · FLOW (NCT03819153)clinicaltrials.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- SELECT: The Trial That Changed What the Class Was For17,604 participants with obesity and cardiovascular disease but no diabetes. Why studying that population specifically was the point.
- The Attribution Problem Running Through Every IndicationHeart, kidney and liver benefits all appear alongside substantial weight reduction. Separating the two is harder than it looks, and mostly has not been done.
- Why Biopsy Endpoints Make Liver Trials HardMASH trials score liver biopsies for inflammation and fibrosis. A pathologist's judgement is a noisier endpoint than a number from a machine.
- STEP UP: Testing Whether More Dose Means More EffectA phase 3b trial of once-weekly semaglutide 7.2 mg in 1,407 adults. Why raising the dose is not a trivial question and what a ceiling would mean.
- How a Molecule Lasts a Month Instead of a WeekWeekly dosing comes from albumin binding. Monthly dosing needs something else - an antibody, and the recycling receptor that keeps it in circulation.